.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Modern medical diagnostics are currently making significant strides toward personalized care. A groundbreaking study reveals how a disease trajectory blood test can predict patient outcomes from just one sample. Researchers at Imperial College London recently developed the VeloCD method for this purpose. This tool analyzes RNA markers to determine if a patient will recover or deteriorate soon. Consequently, doctors can see if an infection is ramping up or winding down without repeated tests.
This innovative approach helps in identifying the specific cause of a fever. For instance, it distinguishes between bacterial and viral origins very efficiently. Furthermore, it accurately assessed children with acute fevers across nine European countries. Specifically, it predicted transitions in healthy adults exposed to flu or COVID-19 pathogens. By predicting the course of illness early, clinicians can provide more targeted treatments. Therefore, the right patient receives the right care at the most optimal time.
Moreover, the test requires only a single time-point sample to yield results. This efficiency reduces the need for repeated measurements over several days significantly. As a result, healthcare staff can triage patients much faster than traditional methods allow. Additionally, the test predicted treatment responses in inflammatory bowel disease after just one dose. Furthermore, the study appeared in the journal Nature Communications recently. However, the team notes that further validation is still necessary before widespread clinical use.
Q1: What is the VeloCD method?
The VeloCD method is a computational approach that analyzes whole-blood RNA to anticipate future clinical states from a single time-point sample.
Q2: Can the test help with COVID-19 and flu?
Yes, the study showed that blood samples collected as early as Day 2 after exposure could accurately predict infection before PCR confirmation.
Q3: Who led the development of this technology?
Researchers from the UK\'s Imperial College London led the study and developed the VeloCD method as a proof-of-concept diagnostic tool.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Imperial College London researchers develop VeloCD, a blood test predicting illness trajectory and treatment response using RNA velocity from one sample....
4 months ago
A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
